Journal of Clinical Endocrinology & Metabolism, Vol 72, 653-659, Copyright © 1991 by Endocrine Society

ARTICLES

Effect of sinorphan, an enkephalinase inhibitor, on plasma atrial natriuretic factor and sodium urinary excretion in cirrhotic patients with ascites

JC Dussaule, JD Grange, JP Wolf, JM Lecomte, C Gros, JC Schwartz, F Bodin and R Ardaillou
INSERM 64, Hopital Tenon, Paris, France.

We examined the acute effects of sinorphan, an inhibitor of enkephalinase, on plasma atrial natriuretic factor (ANF) and urinary sodium excretion in cirrhotic patients with ascites. A single oral dose of sinorphan (100 or 30 mg in 11 and 5 patients, respectively) was administered against placebo according to a double blind cross-over protocol. Basal plasma ANF levels varied over a large range between 2.6- 79 pmol/L. Sinorphan, at a dose of 100 mg, inhibited 70% of plasma enkephalinase activity 60 min after ingestion and elicited simultaneously an increase in plasma ANF and cGMP levels 1.8 and 1.5 times basal values, respectively. There was a transient increase in sodium urinary output without a change in creatinine clearance over the initial 2-h period following drug administration. An increase in urinary cGMP was also observed on a longer period of 6 h. Plasma aldosterone decreased significantly, but the lowest concentration was reached 1 h later than the peak of plasma ANF. Mean blood pressure and PRA were unmodified. The effects of 30 mg sinorphan on plasma ANF, cGMP, and aldosterone were also significant, but less marked than those of the higher dose. Therefore, enkephalinase inhibition transiently increases sodium urinary excretion in cirrhotic patients with ascites via a mechanism that is likely to imply reduction of ANF catabolism. These results suggest that ANF could play a role in the control of sodium homeostasis in liver cirrhosis with ascites.

This article has been cited by other articles:

				G. Sansoe, M. Aragno, R. Mastrocola, J. C. Cutrin, S. Silvano, G. Mengozzi, A. Smedile, F. Rosina, O. Danni, and M. Rizzetto Overexpression of kidney neutral endopeptidase (EC 3.4.24.11) and renal function in experimental cirrhosis Am J Physiol Renal Physiol, June 1, 2006; 290(6): F1337 - F1343. [Abstract] [Full Text] [PDF]

				D. J. Campbell Vasopeptidase Inhibition: A Double-Edged Sword? Hypertension, March 1, 2003; 41(3): 383 - 389. [Abstract] [Full Text] [PDF]

				F. Piquard, R. Richard, A. Charloux, S. Doutreleau, T. Hannedouche, G. Brandenberger, and B. Geny Hormonal, renal, hemodynamic responses to acute neutral endopeptidase inhibition in heart transplant patients J Appl Physiol, August 1, 2002; 93(2): 569 - 575. [Abstract] [Full Text] [PDF]

				A.-M. Duncan, G. M. James, F. Anastasopoulos, A. Kladis, T. A. Briscoe, and D. J. Campbell Interaction Between Neutral Endopeptidase and Angiotensin Converting Enzyme Inhibition in Rats with Myocardial Infarction: Effects on Cardiac Hypertrophy and Angiotensin and Bradykinin Peptide Levels J. Pharmacol. Exp. Ther., April 1, 1999; 289(1): 295 - 303. [Abstract] [Full Text]

				B. Geny, H. Hardy, J. Lonsdorfer, B. Eisenmann, P. Haberey, and F. Piquard Enhanced Natriuretic Response to Neutral Endopeptidase Inhibition in Heart-Transplant Recipients Hypertension, April 1, 1999; 33(4): 969 - 974. [Abstract] [Full Text] [PDF]

				D. J. Campbell, F. Anastasopoulos, A.-M. Duncan, G. M. James, A. Kladis, and T. A. Briscoe Effects of Neutral Endopeptidase Inhibition and Combined Angiotensin Converting Enzyme and Neutral Endopeptidase Inhibition on Angiotensin and Bradykinin Peptides in Rats J. Pharmacol. Exp. Ther., November 1, 1998; 287(2): 567 - 577. [Abstract] [Full Text]